Meeting
2013 ASCO Annual Meeting
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
Authors
Tamas Pinter
Petz Aladar Teaching Hospital, Gyor, Hungary
Tamas Pinter , Esteban Abella , Alvydas Cesas , Adina Croitoru , Jochen Decaestecker , Peter Gibbs , Yevhen Hotko , Jacek Jassem , Galina Petrova Kurteva , Jan Novotny , Seamus O'Reilly , Tomas Salek , May F. Mo , L. Mi Rim Choi , Charles Davic Blanke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00911170
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3575)
DOI
10.1200/jco.2013.31.15_suppl.3575
Abstract #
3575
Poster Bd #
6A
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).
First Author: Tamas Pinter
Poster
2017 ASCO Annual Meeting
Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study.
First Author: Meinolf Karthaus
Poster
2013 ASCO Annual Meeting
A multicenter phase III randomized double-blind placebo controlled trial of pravastatin added to first-line standard chemotherapy in patients with small cell lung cancer (SCLC).
First Author: Michael Seckl
First Author: Axel Grothey